Gilead Sciences fell more than 1.8% to $110.92. According to the news, Gilead Sciences said on Tuesday that the US Food and Drug Administration has clinically suspended the combined drug trial of its two experimental HIV treatments.

Zhitongcaijing · 06/10 15:33
Gilead Sciences fell more than 1.8% to $110.92. According to the news, Gilead Sciences said on Tuesday that the US Food and Drug Administration has clinically suspended the combined drug trial of its two experimental HIV treatments.